| 产品介绍 |
Robatumumab (Sch 717454) 是一种 anti-human IGF-1R (胰岛素样生长因子 1 受体) 抗体。Robatumumab 具有抗肿瘤活性和抗癌细胞增殖活性。Robatumumab 可用于骨肉瘤和尤文肉瘤的研究。
|
|---|
| 生物活性 |
Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research.
|
|---|
| 体外研究 |
Robatumumab (0.02-80 nM; 0.5 or 4 h) downregulates IGF-IR and inhibits both basal and IGF-I-induced phosphorylation of IGF-IR and IRS-1 in SK-N-FI cells.
西域 has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis
| Cell Line: |
SK-N-FI cells |
| Concentration: |
0.02-80 nM |
| Incubation Time: |
0.5 or 4 hours |
| Result: |
Inhibited the IGF-I–stimulated phosphorylation of IGF-IR after treatment 0.5 h.
Resulted in both inhibition of IGF-IR phosphorylation and receptor downregulation after treatment 4 h.
Resulted in a dose-dependent inhibition of the IGF-I–stimulated IRS-1 phosphorylation. |
|
|---|
体内研究
(In Vivo) |
Robatumumab (intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 d) inhibits the SK-N-FI tumor growth in xenograft model.
Robatumumab (intravenous injection; 0.02-0.5 mg/mouse; twice weekly; 35 d) inhibits the osteosarcoma growth in xenograft model.
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 d) inhibits the SJCRH30 and RD rhabdomyosarcoma cell growth in xenograft model.
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 w) blocks effectively pediatric tumor cell proliferation in vivo.
Robatumumab (intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation) modulates the blood vessel formation via its antiangiogenesis effect.
西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: |
Nude mice inoculated with SK-N-FI tumor cells |
| Dosage: |
0.04 or 0.1 mg/mouse |
| Administration: |
Intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 days |
| Result: |
Inhibited the SK-N-FI xenograft tumor by 96% in the 0.04 mg dose group and resulted in 11% tumor regression in the 0.1 mg dose group. |
| Animal Model: |
Nude mice inoculated with SJSA-1 osteosarcoma |
| Dosage: |
0.02, 0.1 or 0.5 mg/mouse |
| Administration: |
Intravenous injection; 0.02, 0.1 or 0.5 mg/mouse; twice weekly; 35 days |
| Result: |
Inhibited the tumor growth by 71%, 82%, and 88% at 0.02, 0.1, and 0.5 mg, respectively, at day 14 after treatment. |
| Animal Model: |
Nude mice inoculated with SJCRH30 and RD rhabdomyosarcoma cells |
| Dosage: |
0.1 or 0.5 mg/mouse |
| Administration: |
Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 days |
| Result: |
Inhibited tumor growth by 39% and 58% at 0.1 and 0.5 mg dose, respectively, in the RD rhabdomyosarcoma model.
Inhibited tumor growth by 37% and 53% at 0.1 and 1 mg dose, respectively, in the SJCRH30 model. |
| Animal Model: |
Nude mice inoculated with SK-N-FI neuroblastoma and SJSA-1 osteosarcoma |
| Dosage: |
0.1 or 0.5 mg/mouse |
| Administration: |
Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 weeks |
| Result: |
Reduced the tumor Ki-67 staining by 38% and along with significant change in SK-N-FI neuroblastoma xenograft.
Reduced the staining of Ki-67 by 37% and 51% after 0.1 and 0.5 mg SCH 717454 treatment, respectively, in the SJSA-1 osteosarcoma xenograft. |
| Animal Model: |
Nude mice inoculated with SJSA-1 osteosarcoma |
| Dosage: |
0.5 mg/mouse |
| Administration: |
Intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation |
| Result: |
Reduced in the intensity of the fluorescent lectin staining by 74% at 0.5 mg dose, showing thinner blood vessels and reduced branches, compared with control IgG1. |
|
| 体内研究 |
Robatumumab (intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 d) inhibits the SK-N-FI tumor growth in xenograft model.
Robatumumab (intravenous injection; 0.02-0.5 mg/mouse; twice weekly; 35 d) inhibits the osteosarcoma growth in xenograft model.
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 d) inhibits the SJCRH30 and RD rhabdomyosarcoma cell growth in xenograft model.
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 w) blocks effectively pediatric tumor cell proliferation in vivo.
Robatumumab (intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation) modulates the blood vessel formation via its antiangiogenesis effect.
西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: |
Nude mice inoculated with SK-N-FI tumor cells |
| Dosage: |
0.04 or 0.1 mg/mouse |
| Administration: |
Intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 days |
| Result: |
Inhibited the SK-N-FI xenograft tumor by 96% in the 0.04 mg dose group and resulted in 11% tumor regression in the 0.1 mg dose group. |
| Animal Model: |
Nude mice inoculated with SJSA-1 osteosarcoma |
| Dosage: |
0.02, 0.1 or 0.5 mg/mouse |
| Administration: |
Intravenous injection; 0.02, 0.1 or 0.5 mg/mouse; twice weekly; 35 days |
| Result: |
Inhibited the tumor growth by 71%, 82%, and 88% at 0.02, 0.1, and 0.5 mg, respectively, at day 14 after treatment. |
| Animal Model: |
Nude mice inoculated with SJCRH30 and RD rhabdomyosarcoma cells |
| Dosage: |
0.1 or 0.5 mg/mouse |
| Administration: |
Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 days |
| Result: |
Inhibited tumor growth by 39% and 58% at 0.1 and 0.5 mg dose, respectively, in the RD rhabdomyosarcoma model.
Inhibited tumor growth by 37% and 53% at 0.1 and 1 mg dose, respectively, in the SJCRH30 model. |
| Animal Model: |
Nude mice inoculated with SK-N-FI neuroblastoma and SJSA-1 osteosarcoma |
| Dosage: |
0.1 or 0.5 mg/mouse |
| Administration: |
Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 weeks |
| Result: |
Reduced the tumor Ki-67 staining by 38% and along with significant change in SK-N-FI neuroblastoma xenograft.
Reduced the staining of Ki-67 by 37% and 51% after 0.1 and 0.5 mg SCH 717454 treatment, respectively, in the SJSA-1 osteosarcoma xenograft. |
| Animal Model: |
Nude mice inoculated with SJSA-1 osteosarcoma |
| Dosage: |
0.5 mg/mouse |
| Administration: |
Intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation |
| Result: |
Reduced in the intensity of the fluorescent lectin staining by 74% at 0.5 mg dose, showing thinner blood vessels and reduced branches, compared with control IgG1. |
|
|---|
| 体内研究 |
Robatumumab (intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 d) inhibits the SK-N-FI tumor growth in xenograft model.
Robatumumab (intravenous injection; 0.02-0.5 mg/mouse; twice weekly; 35 d) inhibits the osteosarcoma growth in xenograft model.
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 d) inhibits the SJCRH30 and RD rhabdomyosarcoma cell growth in xenograft model.
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 w) blocks effectively pediatric tumor cell proliferation in vivo.
Robatumumab (intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation) modulates the blood vessel formation via its antiangiogenesis effect.
西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: |
Nude mice inoculated with SK-N-FI tumor cells |
| Dosage: |
0.04 or 0.1 mg/mouse |
| Administration: |
Intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 days |
| Result: |
Inhibited the SK-N-FI xenograft tumor by 96% in the 0.04 mg dose group and resulted in 11% tumor regression in the 0.1 mg dose group. |
| Animal Model: |
Nude mice inoculated with SJSA-1 osteosarcoma |
| Dosage: |
0.02, 0.1 or 0.5 mg/mouse |
| Administration: |
Intravenous injection; 0.02, 0.1 or 0.5 mg/mouse; twice weekly; 35 days |
| Result: |
Inhibited the tumor growth by 71%, 82%, and 88% at 0.02, 0.1, and 0.5 mg, respectively, at day 14 after treatment. |
| Animal Model: |
Nude mice inoculated with SJCRH30 and RD rhabdomyosarcoma cells |
| Dosage: |
0.1 or 0.5 mg/mouse |
| Administration: |
Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 days |
| Result: |
Inhibited tumor growth by 39% and 58% at 0.1 and 0.5 mg dose, respectively, in the RD rhabdomyosarcoma model.
Inhibited tumor growth by 37% and 53% at 0.1 and 1 mg dose, respectively, in the SJCRH30 model. |
| Animal Model: |
Nude mice inoculated with SK-N-FI neuroblastoma and SJSA-1 osteosarcoma |
| Dosage: |
0.1 or 0.5 mg/mouse |
| Administration: |
Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 weeks |
| Result: |
Reduced the tumor Ki-67 staining by 38% and along with significant change in SK-N-FI neuroblastoma xenograft.
Reduced the staining of Ki-67 by 37% and 51% after 0.1 and 0.5 mg SCH 717454 treatment, respectively, in the SJSA-1 osteosarcoma xenograft. |
| Animal Model: |
Nude mice inoculated with SJSA-1 osteosarcoma |
| Dosage: |
0.5 mg/mouse |
| Administration: |
Intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation |
| Result: |
Reduced in the intensity of the fluorescent lectin staining by 74% at 0.5 mg dose, showing thinner blood vessels and reduced branches, compared with control IgG1. |
|
|---|
| 性状 | Liquid |
|---|
| 溶解性数据 | |
|---|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
|---|
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
|---|
| 参考文献 | |
|---|
浙公网安备 33010802013016号